The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy.
Saved in:
| Title: | The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy. |
|---|---|
| Authors: | Wang JF; First Clinical Medical College of Lanzhou University, Lanzhou, China., Cheng J; First Clinical Medical College of Lanzhou University, Lanzhou, China. Chenggu029@163.com.; Department of Hematology, The First Hospital of Lanzhou University, Lanzhou, China. Chenggu029@163.com. |
| Source: | BMC cancer [BMC Cancer] 2026 Mar 29; Vol. 26 (1). Date of Electronic Publication: 2026 Mar 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-026-15673-4 |
